File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/falgy.2023.1290021
- Scopus: eid_2-s2.0-85180511170
- WOS: WOS:001129397000001
Supplementary
- Citations:
- Appears in Collections:
Article: Hong Kong–Macau Severe Hives and Angioedema Referral Pathway
Title | Hong Kong–Macau Severe Hives and Angioedema Referral Pathway |
---|---|
Authors | |
Keywords | angioedema hereditary hives Hong Kong Macau pathway referral urticaria |
Issue Date | 6-Dec-2023 |
Publisher | Frontiers Media SA |
Citation | Frontiers in Allergy, 2023, v. 4 How to Cite? |
Abstract | Background: Urticaria (defined as the presence of hives, angioedema, or both) can be caused by a variety of etiologies ranging from more common conditions such as chronic spontaneous urticaria (CSU) to rarer conditions such as hereditary angioedema (HAE). Specialist referral may be necessary in cases of severe urticaria or HAE, but access to specialist services remains limited in certain regions, such as the Greater Bay Area (GBA) of China. To address this, the Hong Kong–Macau Severe Hives and Angioedema Referral Pathway (SHARP) was initiated by the Hong Kong Institute of Allergy and Macau Society of Dermatology to promote multidisciplinary collaboration and regional exchange of expertise in the diagnosis and management of severe urticaria. Methods: A nominated task force of dermatologists and immunologists who manage patients with severe urticaria formulated the consensus statements (CS) using the Delphi method. The consensus was defined a priori as an agreement of ≥80%. Results: A total of 24 CS were formulated, including four statements on classifications and definitions, seven statements on diagnosis, and 13 statements on management and referral. The definitions for acute/chronic urticaria and severe CSU were stated. Unnecessary investigations and inappropriate medications were discouraged. The characteristics and recommended approach to suspected bradykinergic angioedema were specified. Stepwise treatment options using second-generation antihistamines, omalizumab, or cyclosporin for patients with CSU were addressed, and the importance of access to HAE-specific medications was emphasized. Furthermore, an integrated referral pathway for patients with severe hives and angioedema was constructed. Conclusion: The SHARP provides guidance for the management and specialist referral of patients with severe hives and angioedema in Hong Kong and Macau. |
Persistent Identifier | http://hdl.handle.net/10722/336566 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, Philip H | - |
dc.contributor.author | Au, Elaine Y L | - |
dc.contributor.author | Cheong, Si-Leong | - |
dc.contributor.author | Chung, Ling | - |
dc.contributor.author | Fan, Ka I | - |
dc.contributor.author | Ho, Marco H K | - |
dc.contributor.author | Leung, Agnes S Y | - |
dc.contributor.author | Chung, Martin M H | - |
dc.contributor.author | Wong, Jane C Y | - |
dc.contributor.author | Coelho, Ricardo | - |
dc.date.accessioned | 2024-02-16T10:31:42Z | - |
dc.date.available | 2024-02-16T10:31:42Z | - |
dc.date.issued | 2023-12-06 | - |
dc.identifier.citation | Frontiers in Allergy, 2023, v. 4 | - |
dc.identifier.uri | http://hdl.handle.net/10722/336566 | - |
dc.description.abstract | <p><strong>Background:</strong> Urticaria (defined as the presence of hives, angioedema, or both) can be caused by a variety of etiologies ranging from more common conditions such as chronic spontaneous urticaria (CSU) to rarer conditions such as hereditary angioedema (HAE). Specialist referral may be necessary in cases of severe urticaria or HAE, but access to specialist services remains limited in certain regions, such as the Greater Bay Area (GBA) of China. To address this, the Hong Kong–Macau Severe Hives and Angioedema Referral Pathway (SHARP) was initiated by the Hong Kong Institute of Allergy and Macau Society of Dermatology to promote multidisciplinary collaboration and regional exchange of expertise in the diagnosis and management of severe urticaria.</p><p><strong>Methods:</strong> A nominated task force of dermatologists and immunologists who manage patients with severe urticaria formulated the consensus statements (CS) using the Delphi method. The consensus was defined <em>a priori</em> as an agreement of ≥80%.</p><p><strong>Results:</strong> A total of 24 CS were formulated, including four statements on classifications and definitions, seven statements on diagnosis, and 13 statements on management and referral. The definitions for acute/chronic urticaria and severe CSU were stated. Unnecessary investigations and inappropriate medications were discouraged. The characteristics and recommended approach to suspected bradykinergic angioedema were specified. Stepwise treatment options using second-generation antihistamines, omalizumab, or cyclosporin for patients with CSU were addressed, and the importance of access to HAE-specific medications was emphasized. Furthermore, an integrated referral pathway for patients with severe hives and angioedema was constructed.</p><p><strong>Conclusion:</strong> The SHARP provides guidance for the management and specialist referral of patients with severe hives and angioedema in Hong Kong and Macau.</p> | - |
dc.language | eng | - |
dc.publisher | Frontiers Media SA | - |
dc.relation.ispartof | Frontiers in Allergy | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | angioedema | - |
dc.subject | hereditary | - |
dc.subject | hives | - |
dc.subject | Hong Kong | - |
dc.subject | Macau | - |
dc.subject | pathway | - |
dc.subject | referral | - |
dc.subject | urticaria | - |
dc.title | Hong Kong–Macau Severe Hives and Angioedema Referral Pathway | - |
dc.type | Article | - |
dc.identifier.doi | 10.3389/falgy.2023.1290021 | - |
dc.identifier.scopus | eid_2-s2.0-85180511170 | - |
dc.identifier.volume | 4 | - |
dc.identifier.eissn | 2673-6101 | - |
dc.identifier.isi | WOS:001129397000001 | - |
dc.identifier.issnl | 2673-6101 | - |